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Genetic Polymorphisms of Glutathione S-Transferase
and Risk of Vitiligo in the Chinese Population
Ling Liu1,2, Chunying Li1,2, Jian Gao1, Kai Li1, Lin Gao1 and Tianwen Gao1
Vitiligo is a common acquired depigmenting disorder characterized by white areas on the skin. Oxidative stress
is a major pathogenesis hypothesis of vitiligo. Glutathione S-transferases (GSTs) are enzymes involved in
protecting cells against chemical toxicity and stress. We hypothesized that the GSTM1- and GSTT1-null
genotypes and GSTP1 polymorphisms were associated with increased risk for vitiligo. In a hospital-based
case–control study of 749 vitiligo patients and 763 age- and sex-frequency-matched healthy controls, GSTM1 and
GSTT1 genotypes and GSTP1 (Ile104Val, Ala113Val, Gly169Asp) polymorphisms were analyzed using the
multiplex PCR and PCR–restriction fragment length polymorphism technique, respectively. We found that the
GSTT1-null genotype was significantly associated with the susceptibility to vitiligo and the GSTM1-null
genotype also showed a trend toward vitiligo association. We further analyzed the combined effect of GSTM1-
null and GSTT1-null genotypes and showed an increased risk of developing vitiligo. By contrast, no statistically
significant association was found between GSTP1 polymorphisms and vitiligo risk. These results suggest that
individuals with homozygous deletion of GSTT1 and/or GSTM1 have a greater predisposition to vitiligo.
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INTRODUCTION
Vitiligo is a relatively common, acquired, and noncontagious
depigmenting disorder of the skin characterized by a
progressive, patchy loss of pigmentation from skin. The
disease may affect individuals of both sexes, with a 0.1–8.8%
incidence worldwide (Handa and Kaur, 1999). Multifactorial
and overlapping pathogenetic mechanisms are proposed for
the disease, but the cellular mechanisms leading to the loss of
functioning epidermal melanocytes remain unclear.
Vitiligo is characterized by incomplete penetrance, multi-
ple susceptibility loci, and genetic heterogeneity (Yang et al.,
2005). Various candidate genes have been proposed for
vitiligo susceptibility, including lymphoid protein tyrosine
phosphatase (PTPN22) (Canton et al., 2005; LaBerge et al.,
2008), angiotensin-converting enzyme (ACE) (Jin et al.,
2004a, b), catechol-O-methyltransferase (COMT) (Tursen
et al., 2002), cytotoxic T-lymphocyte antigen-4 (CTL-4)
(Blomhoff et al., 2005; Itirli et al., 2005), estrogen receptor
1 (ESR1) (Jin et al., 2004a, b), and NACHT leucine-rich repeat
protein 1 (NALP1) (Jin et al., 2007). Most of these genes are
reported to have significant associations, but several studies
have drawn contradictory conclusions (Blomhoff et al., 2005;
Itirli et al., 2005; LaBerge et al., 2008).
Besides the immunological and pathogenic mechanism,
recent data suggest that oxidative stress may be an important
contributor to the pathogenesis of melanocyte death (Bickers
and Athar, 2006; Dell’Anna et al. 2007). The imbalance
between oxidative stress and antioxidation seems to induce
insufficient antioxidation protection or excess production of
reactive oxygen species (ROS) (Passi et al., 1998; Beazley
et al., 1999; Jimbow et al., 2001; Boisseau-Garsaud et al.,
2002; Rokos et al., 2002; Koca et al., 2004; Ines et al., 2006;
Yazici et al., 2006; Arican and Kurutas, 2008).
The glutathione S-transferase (GST) superfamily consists of
the broadly expressed phase II isoenzymes involved in
defense against oxidative stress. They can catalyze the
detoxification of reactive-oxygen regeneration of S-thiolated
proteins and conjugation of glutathione to endogenous and
exogenous electrophile substrates, thus detoxifying a variety
of electrophilic compounds generated by damage to cells
caused by reactive oxygen species (Ma´ria Dusˇinska´ et al.,
2001; Sheehan et al., 2001; Nebert and Vasiliou, 2004). The
polymorphisms in GSTs were correlated with increased
susceptibility to diseases associated with oxidative stress,
such as cancer, diabetes, asthma, and Parkinson’s disease
(Kelada et al., 2003; Hayek et al., 2006; Zannolli et al., 2007;
Csejtei et al., 2008; Masoudi et al., 2009).
The complete GST gene family consists of six subfamilies:
Alpha (GSTA), Mu (GSTM), Omega (GSTO), Pi (GSTP), Theta
(GSTT), and Zeta (GSTZ) (Nebert and Vasiliou, 2004). Among
them, the best-characterized polymorphisms are those in
GSTM1, GSTT1, and GSTP1. The GSTM1 and GSTT1 genes
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are located on chromosomes 1p13.3 and 22q11.23, respec-
tively (Figure 1a). Homozygosity for a nonfunctional allele
causes a GST1-null genotype and may result in loss of
the enzyme activity (Xiao et al., 2008). However, until now,
only a small-sample-sized study has been carried out in
Koreans to investigate the correlation between polymorph-
isms of the GSTM1 and GSTT1 genes and vitiligo suscept-
ibility, suggesting that only the absence of GSTM1, and not
that of GSTT1, was associated with the risk of vitiligo (Uhm
et al., 2007).
The human GSTP1 gene, mapped to chromosome 11q13,
has been reported to have three common polymorphisms in
the exons that lead to missense mutations (313A4G,
341C4T, and 506G4A) (Figure 1b). The single-nucleotide
polymorphism A-to-G transition at nucleotide 313 (GSTP1
Ile104Val, rs1695) causes the missense mutation of codon
104 from ATC (isoleucine) to GTC (valine) (Ahmad et al.,
1990). The C-to-T substitution at 341 (GSTP1 Ala113Val,
rs1138272) results in the change of GCG (alanine) to GTG
(valine) in codon 113 (Ali-Osman et al., 1997). The G-to-A
substitution at 506 (GSTP1 Gly169Asp, rs41462048) is also a
missense mutation that changes GGC (glycine) to GAC
(aspartic acid) in codon 169 (Kitteringham et al., 2007). These
changes of amino acids may lead to small or significant
alterations in the activity and function of the enzyme. Hence,
we hypothesized that the abovementioned common GST
polymorphisms were associated with susceptibility to vitiligo
in the Chinese population and tested this hypothesis in our
hospital-based case–control study.
RESULTS
Characteristics of the study subjects
This study included 749 Han Chinese patients with vitiligo
and 763 age- and sex-matched controls. The mean age was
24.7±13.6 years for cases and 26.4±13.3 years for controls
(P¼0.667), and the frequency distributions between 11 and
20 years were 41.8 and 41.9% in the cases and the controls,
respectively. The frequency distributions for men and women
were 55.3 and 44.7% in the cases and 54.1 and 45.9% in the
controls (P¼0.655), respectively (Supplementary Table 1).
Genotype distribution of the GSTM1 and GSTT1 polymorphism
between the cases and controls
The frequency of the null type of GSTT1 in vitiligo
patients was significantly overrepresented compared with
the controls (Po0.001). A significantly increased risk of
vitiligo susceptibility was associated with the GSTT1-null
type (adjusted odds ratio (OR) 1.42, 95% confidence interval
(CI) 1.16–1.75), whereas the GSTM1-null genotype showed
only a borderline increased vitiligo risk (P¼ 0.059, adjusted
OR 1.22, 95% CI 0.99–1.49) (Table 1). We further analyzed
the combined effect of GSTM1 and GSTT1 by using
both GSTM1- and GSTT1-present types as the reference
(Table 2). The results suggested a significant association of
vitiligo risk with GSTT1-present/GSTM1-null type (adjusted
OR 1.58, 95% CI 1.20–2.07), GSTT1-null/GSTM1-present
type (adjusted OR 1.98, 95% CI 1.46–2.69), or GSTT1-null/
GSTM1-null type (adjusted OR 1.71, 95% CI 1.28–2.28), and















Promoter Exon1 2 3 4
Ile104Val(rs1695)
AA AG GG CC GG GA AACT TT
Ala113Val(rs1138272) Gly169Asp(rs41462048)
5 6 7 3′ UTR
Figure 1. Gel electrophoresis for GSTs. (a). Gel electrophoresis of amplicons for GSTM1 (215 bp) and GSTT1 (480 bp) to determine combined genotypes,
in comparison with b-globin (268 bp). Note that the heterozygous status (present/null) of the GSTM1/GSTT1 genes cannot be differentiated from the
homozygous status (present/present). Only homozygosity for the nonfunctional allele (null/null) causing a GST-null genotype can result in a loss of the
enzyme activity. (b) Location of the three tested missense variants—Ile104Val, Ala113Val, and Gly169Asp—in the GSTP1 gene and the restriction fragment
digest results after gel electrophoresis (see Results). (c) Genomic sequence for the three Ile104Val genotypes.
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Genotype distribution of the GSTP1 polymorphisms between
the cases and the controls
The GSTP1 Ile104Val polymorphism was analyzed using the
PCR–restriction fragment length polymorphism technique
using BsmAI to digest the 176-bp PCR amplification products,
which resulted in 91- and 85-bp fragments in the case
of the Val allele (Figure 1c). The distribution of all the
GSTP1 Ile104Val genotypes among the controls was in
agreement with the Hardy–Weinberg equilibrium (w2¼
0.311, P¼0.577). The frequency of the alleles and genotypes
in vitiligo patients did not show significant overrepresentation
compared with the controls (P¼0.103) (Table 1). The
frequency of the Ile/Val genotypes in vitiligo patients
showed a tendency of reduced vitiligo risk (adjusted
OR 0.84, 95% CI 0.67–1.05). When using the combined
genotype (Ile/Ileþ Ile/Val) as the reference, the Val/Val
genotype was not associated with a significantly increased
risk of vitiligo (P¼ 0.131, adjusted OR 1.50, 95% CI
0.89–2.53).
The single-nucleotide polymorphism GSTP1 Ala113Val
was analyzed using the PCR–restriction fragment length
polymorphism technique with AciI, which cuts only the Ala
allele, resulting in 111- and 109-bp fragments (Figure 1b).
The Val allele was rarely detected (only one Ala/Val genotype
Table 1. Genotype and allele frequencies of the GSTs polymorphism among the cases and controls and the
associations with risk of vitiligo
Cases (n=749) Controls (n=763)1
Genotypes n % n % P2 Crude OR (95% CI) Adjusted OR (95% CI)3
GSTM1 — — — — 0.059 — —
Present (+) 323 43.1 366 48.0 1.00 (reference) 1.00 (reference)
Null () 426 56.9 397 52.0 1.22 (0.99–1.49) 1.22 (0.99–1.49)
GSTT1 — — — — o0.001 — —
Present (+) 396 52.9 468 61.3 1.00 (reference) 1.00 (reference)
Null () 353 47.1 295 38.7 1.41 (1.15–1.74) 1.42 (1.16–1.75)
GSTP1 Ile104Val — — — — 0.103 — —
Ile/Ile 508 67.8 499 65.4 1.00 (reference) 1.00 (reference)
Ile/Val 205 27.4 239 31.3 0.84 (0.67–1.05) 0.84 (0.67–1.05)
Val/Val 36 4.8 25 3.3 1.41 (0.84–2.40) 1.42 (0.84–2.41)
Ile/Ile +Ile/Val 713 95.2 738 96.7 0.131 1.00 (reference) 1.00 (reference)
Val/Val 36 4.8 25 3.3 1.49 (0.89–2.51) 1.50 (0.89–2.53)
Val allele — 18.5 — 18.9 0.814 — —
95% CI, 95% confidence interval; OR, odds ratio.
1The observed genotype frequencies among the control subjects were in agreement with the Hardy–Weinberg equilibrium (w2=0.311, P=0.577).
2Two-sided w2 test for either genotype distributions or allele frequencies between the cases and controls.
3ORs were obtained from a logistic regression model with adjustment for age and sex.
Table 2. Frequencies of the combined genotypes of GSTM1 and GSTT1 among the cases and controls and the
associations with risk of vitiligo
Cases (n=749) Controls (n=763)
Combined genotypes n % n % P1 Crude OR (95% CI) Adjusted OR (95% CI)2
GSTT1/GSTM1 — — — — o0.001 — —
Present/present 157 21.0 238 31.2 1.00 (reference) 1.00 (reference)
Present/null 239 31.9 230 30.1 1.58 (1.20–2.07) 1.58 (1.20–2.07)
Null/present 166 22.2 128 16.8 1.97 (1.45–2.67) 1.98 (1.46–2.69)
Null/null 187 24.9 167 21.9 1.70 (1.27–2.27) 1.71 (1.28–2.28)
Ptrend o0.001
95% CI, 95% confidence interval; OR, odds ratio.
1Two-sided w2 test for either genotype distributions between the cases and controls.
2ORs were obtained from a logistic regression model with adjustment for age and sex.
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was present in 200 control subjects), so no further statistical
analysis was carried out. GSTP1 Gly169Asp was analyzed using
the PCR–restriction fragment length polymorphism technique
with BsaJI, which cuts only the Gly allele (Figure 1b). The Asp
allele could not be detected in any of the controls or the vitiligo
patients, so all individuals recruited in this study were inferred to
be homozygous for the Gly allele.
Stratified analysis of the GSTM1, GSTT1, and GSTP1 Ile104Val
polymorphisms and different clinical types of vitiligo
We investigated the effects of GSTM1 and GSTT1 poly-
morphisms on the five vitiligo clinical types. As shown in
Table 3, the GSTM1-null type was significantly associated
with vitiligo susceptibility in focal vitiligo and universal
vitiligo (adjusted OR 1.61, 95% CI 1.15–2.25; and adjusted
OR 1.72, 95% CI 1.11–2.68, respectively). The GSTT1-null
type was significantly associated with vitiligo susceptibility
in three subtypes (acrofacial vitiligo, adjusted OR 1.85, 95%
CI 1.04–3.30; vulgaris vitiligo, adjusted OR 1.36, 95% CI
1.06–1.74; and universal vitiligo, adjusted OR 1.64, 95%
CI 1.08–2.51).
We further used both present types of GSTM1 and GSTT1 as
references to carry out a stratification analysis on the association
between combined variant genotypes (GSTT1-present/GSTM1-
null type, GSTT1-null/GSTM1-present type, and GSTT1-null/
GSTM1-null type) and the risk of vitiligo by clinical type
(Table 4). The GSTT1-present/GSTM1-null type showed sig-
nificant association with focal vitiligo (adjusted OR 2.10, 95%
CI 1.33–3.31) and a marginally significant association with
vulgaris vitiligo (adjusted OR 1.38, 95% CI 0.99–1.92). The
GSTT1-null/GSTM1-null type was associated with susceptibility
in focal vitiligo and in universal vitiligo (adjusted OR 2.11, 95%
CI 1.30–3.44; and adjusted OR 2.65, 95% CI 1.45–4.86,
respectively). The GSTT1-null/GSTM1-present type was asso-
ciated with increased risks for other vitiligo subtypes (focal
vitiligo, adjusted OR 1.90, 95% CI 1.12–3.22; acrofacial vitiligo,
adjusted OR 3.49, 95% CI 1.51–8.07; vulgaris vitiligo, adjusted
OR 1.90, 95% CI 1.32–2.74).
We carried out a stratification analysis of the association
between GSTP1 Ile104Val variant genotypes and the risk of
vitiligo by clinical type using the combined genotype
(Ile/Ileþ Ile/Val) as the reference (Ile/Ileþ Ile/Val vs. Val/Val).
As shown in Table 5, the frequency of the variant genotype
Val/Val was significantly higher among the universal vitiligo
cases than among the controls (P¼ 0.024). Accordingly, the
Val/Val genotype was associated with a higher risk for
universal vitiligo (adjusted OR 2.60; 95% CI 1.13–5.95). The
Val/Val genotype was not associated with a risk for the other
four vitiligo subtypes (P¼ 0.544, P¼ 0.916, P¼0.806, and
P¼0.213, respectively).
DISCUSSION
GSTs have an important function in the defense against
oxidative stress. The homozygosity for null alleles or those
encoding low-activity variants may be associated with
deleterious biochemical consequences; hence, the poly-
morphisms in GSTs are correlated with increased suscept-
ibility to diseases associated with oxidative stress, such as
cancer, diabetes, asthma, and Parkinson’s disease, and may
also be associated with rosacea, UV sensitivity, atopic
dermatitis, and vitiligo (Kerb et al., 1997; Safronova et al.,
2003; Vavilin et al., 2003; Saadat et al., 2004; Saadat, 2006;
Yazici et al., 2006; Uhm et al., 2007).
In this study, we found that the GSTT1-null genotype
showed a significant association with susceptibility to vitiligo,
whereas the GSTM1-null genotype showed a trend toward
association with vitiligo. We did not find evidence for an
association between the GSTP1 gene variants and vitiligo in
the Chinese subjects, suggesting that GSTP1 gene allelic
variants may not have a major function in susceptibility to the
disease.
The genotypic distributions of GSTM1 and GSTT1 are
different among ethnic groups and diseases. In a previously
published study of 310 vitiligo cases and 549 controls, it was
suggested that the GSTM1-null type, and not the GSTT1-null
type, might be associated with vitiligo susceptibility (Uhm
et al., 2007). However, we found that a significantly
increased risk for vitiligo susceptibility was associated with
the GSTT1-null type, whereas the GSTM1-null genotype
showed only slightly increased vitiligo risk. We further
Table 3. Stratification analysis of the GSTM1 and GSTT1 genotypes associated with vitiligo risk due to different
clinical types of vitiligo
GSTM1 (vitiligo patient) GSTT1 (vitiligo patient)
Present (+) Null () Present (+) Null ()
Clinical types n (case/control) n (%) n (%) OR (95% CI)1 n (%) n (%) OR (95% CI)1
Total 749/763 — — — — — —
Segment vitiligo 43/763 21 (48.8) 22 (51.2) 1.02 (0.55–1.89) 22 (51.2) 21 (48.8) 1.58 (0.85–2.95)
Focal vitiligo 181/763 66 (36.5) 115 (63.5) 1.61 (1.15–2.25) 100 (55.3) 81 (44.7) 1.31 (0.94–1.82)
Acrofacial vitiligo 50/763 26 (52.0) 24 (48.0) 0.85 (0.48–1.51) 23 (46.0) 27 (54.0) 1.85 (1.04–3.30)
Vulgaris vitiligo 377/763 176 (46.7) 201 (53.3) 1.05 (0.82–1.34) 203 (53.9) 174 (46.1) 1.36 (1.06-1.74)
Universal vitiligo 98/763 34 (34.7) 64 (65.3) 1.72(1.11–2.68) 48 (49.0) 50 (51.0) 1.64 (1.08–2.51)
95% CI, 95% confidence interval; OR, odds ratio.
1ORs were obtained from a logistic regression model with adjustment for age and sex.
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analyzed the combined effect of both GSTM1-null and
GSTT1-null genotypes on the manifestation of vitiligo. The
significance in the trend test suggests that the patients
carrying both null types may be at a higher risk for vitiligo,
which may be confirmed in studies with larger sample sizes
(Ptrendo0.001).
We investigated the effects of GSTM1 and GSTT1
polymorphisms on the five vitiligo clinical types. The
GSTM1-null type was significantly associated with suscept-
ibility to focal vitiligo and universal vitiligo. The GSTT1-null
type was significantly associated with susceptibility to
acrofacial vitiligo, vulgaris vitiligo, and universal vitiligo.
When we further used the GSTT1-present/GSTM1-present
type as the reference, the GSTT1-present/GSTM1-null type
showed significant association with a higher risk for focal
vitiligo and a marginally significant association with vulgaris
vitiligo. The GSTT1-null/GSTM1-null type was associated
with susceptibility to focal vitiligo and universal vitiligo. The
GSTT1-null/GSTM1-present type was associated with in-
creased risks for other vitiligo subtypes (focal vitiligo,
acrofacial vitiligo, and vulgaris vitiligo).
It has been reported that patients with a particular GSTP1
genotype could eliminate reactive oxygen species quickly
and had lower levels of oxidative DNA damage (Matsui et al.,
2000), which suggested that GSTP1 variants may affect
GSTP1 enzyme activity greatly. The three GSTP1 polymorph-
isms assayed in this study were missense mutations, Ile-Val,
Ala-Val, and Gly-Asp. However, the frequencies of the
three GSTP1 polymorphisms in the vitiligo patients showed
no significant over-representation compared with the con-
trols, and nearly all individuals recruited in this study were
homozygous for Ala113Val and Gly169Asp wild types.
In summary, we provide evidence that the absence of the
GSTT1 or GSTM1 gene may be a risk factor for vitiligo,
whereas the GSTP1 gene allelic variants assayed in our study
may not have a major effect in the etiology of vitiligo. Future
studies may focus on the functional analyses of these genes in
disease susceptibility. Because of uncontrolled biases in the
selection of the subjects and the limited sample size, larger
and population-based studies including more single-nucleo-
tide polymorphisms in genes involved in oxidative stress are
warranted to confirm these findings.
Table 4. Stratification analysis of the combined genotypes associated with vitiligo risk due to different clinical types
of vitiligo
Combined genotypes of GSTT1/GSTM1 (vitiligo patients)
Present/present Present/null Null/present Null/null
Clinical types n (case/control) n (%) n (%) OR (95% CI)1 n (%) OR (95% CI)1 n (%) OR(95% CI)1
Total 749/763 — — — — — — —
Segment vitiligo 43/763 10 (23.3) 12 (27.9) 1.28 (0.54–3.05) 11 (25.6) 2.10 (0.86–5.14) 10 (23.2) 1.56 (0.63–3.86)
Focal vitiligo 181/763 33 (18.2) 67 (37.0) 2.10 (1.33–3.31) 33 (18.3) 1.90 (1.12–3.22) 48 (26.5) 2.11 (1.30–3.44)
Acrofacial vitiligo 50/763 9 (18.0) 14 (28.0) 1.61 (0.68–3.79) 17 (34.0) 3.49 (1.51–8.07) 10 (20.0) 1.58 (0.63–3.97)
Vulgaris vitiligo 377/763 87 (23.1) 116(30.8) 1.38 (0.99–1.92) 89 (23.6) 1.90 (1.32–2.74) 85 (22.5) 1.38 (0.97–1.98)
Universal vitiligo 98/763 18 (18.4) 30 (30.6) 1.72 (0.93–3.17) 16 (16.3) 1.65 (0.81–3.36) 34 (34.7) 2.65 (1.45–4.86)
95% CI, 95% confidence interval; OR, odds ratio.
1ORs were obtained from a logistic regression model with adjustment for age and sex.




Clinical types n (case/control1) n % n % Crude OR (95% CI) Adjusted OR (95% CI)2 P
Total 749/763 — — — — — — —
Segment vitiligo 43/763 41/738 95.4/96.7 2/25 4.6/3.3 1.44 (0.33–6.29) 1.59 (0.36–7.06) 0.544
Focal vitiligo 181/763 175/738 96.7/96.7 6/25 3.3/3.3 1.01 (0.41–2.51) 1.05 (0.42–2.61) 0.916
Acrofacial vitiligo 50/763 48/738 96.0/96.7 2/25 4.0/3.3 1.23 (0.28–5.35) 1.20 (0.28–5.25) 0.806
Vulgaris vitiligo 377/763 359/738 95.2/96.7 18/25 4.8/3.3 1.48 (0.80–2.75) 1.48 (0.80–2.76) 0.213
Universal vitiligo 98/763 90/738 91.8/96.7 8/25 8.2/3.3 2.62 (1.15–5.99) 2.60 (1.13–5.95) 0.024
95% CI, 95% confidence interval; OR, odds ratio.
1The observed genotype frequencies among the control subjects were in agreement with the Hardy–Weinberg equilibrium (w2=0.311, P=0.577).
2ORs were obtained from a logistic regression model with adjustment for age and sex.
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MATERIALS AND METHODS
Patients and controls
The patients and controls were selected as described in our previous
research (Li et al., 2008). There were 749 vitiligo patients and 763
control subjects who were recruited from Xijing Hospital, Fourth
Military Medical University. Only Han Chinese (reflecting more than
90% of the population of China) patients were included in the
analysis to avoid genotype frequency variations due to the presence
of different ethnic groups. The vitiligo-free controls were matched
to the cases by age (±5 years), sex, and ethnicity (Supplementary
Table 1). The research protocol was approved by the ethics review
board of Fourth Military Medical University, and all patients gave
signed informed consent. The study was conducted according to the
Declaration of Helsinki Principles.
Genotyping
GSTM1 and GSTT1 genotypes were determined by multiplex PCR
using the b-globin gene as a positive control for amplification. The
presence of GSTM1 and GSTT1 yielded specific products of 215 and
480 bp, respectively, whereas the control b-globin product was
268 bp (Figure 1a). Heterozygous (present/null) status cannot be
differentiated from homozygous (present/present) status, so a specific
PCR product indicates at least one functional allele. GSTM1 or
GSTT1 deleted in both alleles (GSTM1 null or GSTT1 null) would
result in the absence of GSTM- or GSTT1-specific products. The
GSTP1 polymorphisms were determined using the PCR–restriction
fragment length polymorphism method (Figure 1b and c) (Supple-
mentary Table 2).
Statistical analysis
We used the w2 test to evaluate the differences in frequency
distributions of selected demographic variables between the cases
and the controls. Unconditional univariate and multivariate logistic
regression analyses were carried out to obtain the crude and adjusted
ORs for risk of vitiligo and their 95% CIs. Two-sided tests of
statistical significance were carried out using the SAS software
(version 10.0; SAS Institute, Inc., Cary, NC).
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